EirGenix ha firmado el acuerdo de licencia comercial para su segundo biosimilar de HER2, EG1206A

Exclusive Licensing Agreement: EirGenix Inc. has signed a second exclusive global licensing agreement with Sandoz AG for the commercialization of its breast cancer biosimilar, EG1206A, which is a biosimilar of Roche's pertuzumab. The agreement excludes several Asian territories and includes potential payments of up to $152 million for EirGenix.

Clinical Progress and Market Potential: EG1206A has completed its pharmacokinetic study and received positive feedback from both the FDA and EMA, allowing for an expedited development pathway. This biosimilar aims to expand treatment options for the approximately 2.3 million global breast cancer patients, particularly those with HER2-positive disease.

Sandoz's Market Leadership: Sandoz is a global leader in affordable medications, with a diverse portfolio of around 1,300 products. The company aims to enhance healthcare access and reported net sales of $10.4 billion in 2024, showcasing its significant impact on the healthcare system.

EirGenix's Growth and Capabilities: EirGenix is advancing its biosimilar development through reverse engineering technologies and is expanding its product portfolio. The company is positioned to become a key player in the global biosimilars market, supported by its production capabilities and favorable regulatory environment.